Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates
Key Highlights
- ➤Pediatric ADHD Evoke scans increased 373% year over year.
- ➤Firefly's proprietary repository exceeds 200,000 standardized EEG/ERP brain scans.
- ➤Firefly is cross-selling NeuroSigma's Monarch eTNS System through its clinician network.
- ➤Monarch eTNS is FDA-cleared as a non-drug prescription treatment for pediatric ADHD.
Expert Statements
Greg Lipschitz, Chief Executive Officer of Firefly Neuroscience
“The 373% increase in our pediatric ADHD scan volume reflects what we believe is accelerating market adoption of objective, measurement-driven psychiatry.”
Greg Lipschitz, Chief Executive Officer of Firefly Neuroscience
“Our commercial priority is to build on this momentum by helping existing and new clinical partners deploy the Monarch eTNS(®) treatment alongside the Evoke™ platform across our expanding network.”
KENMORE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today announced a 373% year-over-year (“YoY”) increase (a 4.7-fold gain) in commercial utilization of its FDA-510(k)-cleared Evoke™ platform for pediatric and adolescent patients (under age 18) exhibiting symptoms of ADHD, attention, or focus deficits.
This accelerated commercial utilization highlights expanding clinical adoption and revenue-generating scale across Firefly's neurodiagnostic platform, which converts complex electrophysiological data into objective brain-function assessments:
Get started
Create a free account to read the full story.
